Aldeyra Therapeutics, Inc. 8-K

What Happened
Aldeyra Therapeutics, Inc. filed a Current Report on Form 8-K on May 1, 2026 (Item 7.01) to disclose an updated corporate overview related to its New Drug Application (NDA) for reproxalap in dry eye disease. The Corporate Overview (furnished as Exhibit 99.1) includes standardized treatment estimates and confidence intervals for the primary endpoints of all proposed commercial dosing-regimen efficacy trials submitted in the reproxalap NDA, plus Aldeyra’s abbreviated interpretations of the U.S. FDA’s positions on those primary endpoints and Aldeyra’s own positions.

Key Details

• Filing date: May 1, 2026 (Current Report on Form 8-K, Item 7.01).
• Document: Corporate Overview furnished as Exhibit 99.1 and incorporated by reference.
• Content disclosed: standardized treatment estimates and confidence intervals for primary endpoints of reproxalap NDA efficacy trials for dry eye disease.
• Also disclosed: Aldeyra’s interpretations of FDA positions on the primary endpoints and Aldeyra’s positions.

Why It Matters
This disclosure gives investors direct access to the company’s summary of clinical efficacy expectations and how Aldeyra views the FDA’s stance on key trial endpoints—information that bears on the regulatory risk and commercial prospects of reproxalap. While the 8-K does not announce regulatory decisions or financial results, the updated overview can help investors assess the strength of the clinical evidence supporting the NDA and the degree of alignment (or disagreement) between Aldeyra and the FDA on trial endpoints.